| Jennifer Pavloski, AP SOCIAL WORKER | |
|
108 E North St, Friendship, WI 53934-9443 | |
| (608) 339-4505 | |
| (608) 339-4593 |
| Full Name | Jennifer Pavloski |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 108 E North St, Friendship, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467997957 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 127776 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Pavloski, AP SOCIAL WORKER 108 E North St, Friendship, WI 53934-9443 Ph: (608) 339-4505 | Jennifer Pavloski, AP SOCIAL WORKER 108 E North St, Friendship, WI 53934-9443 Ph: (608) 339-4505 |
News Archive
CQ reports that details are emerging regarding House Democrats' Plan. "The health care overhaul under development by House Democrats would subsidize insurance premiums for families earning as much as four times the poverty level, while expanding Medicaid and improving its payments to health providers."
Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso's imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.
Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
The U.S. Food and Drug Administration today issued warning letters to five distributors for various violations of the Federal Food, Drug, and Cosmetic Act (FDCA) including unsubstantiated claims and poor manufacturing practices.
› Verified 8 days ago
Meagan Lynn Grabarski, MPSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 108 E North St, Friendship, WI 53934 Phone: 608-434-0022 |